Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway

Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway

Abstract Background Non-alcoholic fatty liver disease (NAFLD) has been well defined as a common chronic liver metabolism disorder. Statins as a first-line therapeutic treatment had some side effects. Here, we found that Fumigaclavine C (FC) was collected from endophytic Aspergillus terreus via the r...

Full description

Bibliographic Details
Main Authors: Wanguo Yu, Yaxin Gao, Zaoya Zhao, Xiufeng Long, Yi Yi, Shuo Ai
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Fumigaclavine C
Non-alcoholic fatty liver disease
Anti-obesity
Protein prenylation
Online Access:https://doi.org/10.1186/s12906-023-04110-9

Internet

https://doi.org/10.1186/s12906-023-04110-9

Similar Items